Methylene blue vs Modafinil

Methylene blue (A-tier) vs Modafinil (A-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

Methylene blue · tier A

Methylene blue is a redox-active phenothiazinium drug. Its FDA approval treats acquired methemoglobinemia; cognition evidence is a small acute experiment, not a chronic nootropic program.

A 26-person single-exposure oral study found fMRI changes and a small memory-retrieval signal. It does not establish durable cognitive benefit, a chronic regimen, or long-term safety.

26 people in the acute oral fMRI trial · half-life about 24 h in the reviewed IV product's human PK; not a chronic oral nootropic value · focus

Modafinil · tier A

Modafinil is an oral Schedule IV wake-promoting drug approved for excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift-work disorder. Those indications do not establish broad cognitive enhancement in rested healthy people.

Modafinil improves wakefulness in defined sleep disorders. A small severe sleep-deprivation experiment found task-specific effects, but sleep deprivation is not rested-user evidence and does not establish broad cognition, productivity, mood, or long-term safety claims.

3 approved excessive-sleepiness settings · half-life about 15 h for oral modafinil in the label PK record · focus

at a glance

• Methylene blue: tier A · 26 people in the acute oral fMRI trial
• Modafinil: tier A · 3 approved excessive-sleepiness settings

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.